Full name

A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 (Camliplixant) in Adult Participants With Refractory Chronic Cough, Including Unexplained Chronic Cough

NCT Number
NCT05600777
Geography
US
Non-US
Locations

Australia, Czechia, Germany, India, Republic of Korea, New Zealand, Slovakia, Taiwan, United Kingdom, United States

Primary Endpoints

24-Hour Cough Frequency. Week 24

External Link
https://clinicaltrials.gov/study/NCT05600777
Order
2
Disease
RCC
Menu title
A 24-Week Study of the Efficacy and Safety of BLU-5937 (Camliplixant) in Adults With Refractory Chronic Cough (CALM-2)
Version
AAAAI 2025
Phase
3
Status
Not yet recruiting